검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Corticosteroid |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ADC |
Overview Target | Carcinoma, Non-Small-Cell Lung |
Overview Indication | Carcinoma, Non-Small-Cell Lung |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | binds to an inactive glucocorticoid receptor |
MoA Biomarker | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Recombinant Sgp130 attenuates alkali-burn cornea through inhibition of IL-6 trans-signaling: From production to therapeutic application.. Interleukin-6 (IL-6) is a highly promising therapeutic target across numerous pathological conditions. This cytokine mediates two distinct downstream signaling cascades: classic signaling, which primarily regulates regenerative and anti-inflammatory processes; a… |
Clinical Primary efficacy | ORR 5.6% |
Clinical ORR | 5.6% |
Clinical Result source | ClinicalTrials.gov NCT02472366 |
Clinical Data Tier / Score | A · 36 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Corticosteroid |
Overview Company | Merck Sharp & Dohme LLC |
Overview Modality | ADC |
Overview Target | Carcinoma, Non-Small-Cell Lung |
Overview Indication | Carcinoma, Non-Small-Cell Lung |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | binds to an inactive glucocorticoid receptor |
MoA Biomarker | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Recombinant Sgp130 attenuates alkali-burn cornea through inhibition of IL-6 trans-signaling: From production to therapeutic application.. Interleukin-6 (IL-6) is a highly promising therapeutic target across numerous pathological conditions. This cytokine mediates two distinct downstream signaling cascades: classic signaling, which primarily regulates regenerative and anti-inflammatory processes; a… |
Clinical Primary efficacy | ORR 5.6% |
Clinical ORR | 5.6% |
Clinical Result source | ClinicalTrials.gov NCT02472366 |
Clinical Data Tier / Score | A · 36 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 12일 (1일 전) |
추천 비교
추천 비교